Drug Details
| General Information of the Drug (ID: DR6736) | ||||
|---|---|---|---|---|
| Name |
Thalidomide
|
|||
| Synonyms |
Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Multiple myeloma [ICD-11: 2A83] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.4 mL/min/kg
Elimination
0.5% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 4.7 hours
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 22.12781 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.4%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.95 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 0.0525 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C13H10N2O4
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
|
|||
| InChI |
1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
|
|||
| InChIKey |
UEJJHQNACJXSKW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 50-35-1
|
|||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MEK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ULK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | VEGFC | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | KG-1 | CVCL_0374 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide and thalidomide combination induces autophagy along with apoptosis in acute myeloid cell lines. | |||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | KG-1 | CVCL_0374 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl-xL, Leading to Apoptosis in Acute Myeloid Leukemia Cell Lines. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Tumor necrosis factor (TNF) | Molecule Info | [4] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | Cytokine-cytokine receptor interaction | |||
| 3 | NF-kappa B signaling pathway | |||
| 4 | Sphingolipid signaling pathway | |||
| 5 | mTOR signaling pathway | |||
| 6 | Apoptosis | |||
| 7 | TGF-beta signaling pathway | |||
| 8 | Osteoclast differentiation | |||
| 9 | Antigen processing and presentation | |||
| 10 | Toll-like receptor signaling pathway | |||
| 11 | NOD-like receptor signaling pathway | |||
| 12 | RIG-I-like receptor signaling pathway | |||
| 13 | Hematopoietic cell lineage | |||
| 14 | Natural killer cell mediated cytotoxicity | |||
| 15 | T cell receptor signaling pathway | |||
| 16 | Fc epsilon RI signaling pathway | |||
| 17 | TNF signaling pathway | |||
| 18 | Adipocytokine signaling pathway | |||
| 19 | Type II diabetes mellitus | |||
| 20 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 21 | Type I diabetes mellitus | |||
| 22 | Alzheimer's disease | |||
| 23 | Amyotrophic lateral sclerosis (ALS) | |||
| 24 | Pertussis | |||
| 25 | Legionellosis | |||
| 26 | Leishmaniasis | |||
| 27 | Chagas disease (American trypanosomiasis) | |||
| 28 | African trypanosomiasis | |||
| 29 | Malaria | |||
| 30 | Toxoplasmosis | |||
| 31 | Amoebiasis | |||
| 32 | Tuberculosis | |||
| 33 | Hepatitis C | |||
| 34 | Hepatitis B | |||
| 35 | Influenza A | |||
| 36 | HTLV-I infection | |||
| 37 | Herpes simplex infection | |||
| 38 | Proteoglycans in cancer | |||
| 39 | Asthma | |||
| 40 | Inflammatory bowel disease (IBD) | |||
| 41 | Systemic lupus erythematosus | |||
| 42 | Rheumatoid arthritis | |||
| 43 | Allograft rejection | |||
| 44 | Graft-versus-host disease | |||
| 45 | Hypertrophic cardiomyopathy (HCM) | |||
| 46 | Dilated cardiomyopathy | |||
| NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
| 2 | IL2 Signaling Pathway | |||
| 3 | IL3 Signaling Pathway | |||
| 4 | IL4 Signaling Pathway | |||
| 5 | Leptin Signaling Pathway | |||
| 6 | RANKL Signaling Pathway | |||
| 7 | IL1 Signaling Pathway | |||
| Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
| 2 | Wnt signaling pathway | |||
| Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | Click to Show/Hide | ||
| Pathway Interaction Database | IL27-mediated signaling events | Click to Show/Hide | ||
| 2 | Canonical NF-kappaB pathway | |||
| 3 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 4 | Angiopoietin receptor Tie2-mediated signaling | |||
| 5 | Signaling events mediated by HDAC Class I | |||
| 6 | TNF receptor signaling pathway | |||
| 7 | Ceramide signaling pathway | |||
| 8 | amb2 Integrin signaling | |||
| 9 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 10 | IL23-mediated signaling events | |||
| 11 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 12 | Caspase Cascade in Apoptosis | |||
| 13 | Cellular roles of Anthrax toxin | |||
| 14 | Downstream signaling in naï | |||
| 15 | ||||
| Reactome | Transcriptional regulation of white adipocyte differentiation | Click to Show/Hide | ||
| 2 | TNFR1-induced proapoptotic signaling | |||
| 3 | Regulation of TNFR1 signaling | |||
| 4 | TNFR1-induced NFkappaB signaling pathway | |||
| 5 | TNFR1-mediated ceramide production | |||
| 6 | TNFR2 non-canonical NF-kB pathway | |||
| 7 | TNF signaling | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | Monoamine Transport | |||
| 3 | SIDS Susceptibility Pathways | |||
| 4 | TGF Beta Signaling Pathway | |||
| 5 | Cytokines and Inflammatory Response | |||
| 6 | MAPK Signaling Pathway | |||
| 7 | EV release from cardiac cells and their functional effects | |||
| 8 | FAS pathway and Stress induction of HSP regulation | |||
| 9 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 10 | Cardiac Hypertrophic Response | |||
| 11 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 12 | Aryl Hydrocarbon Receptor | |||
| 13 | Apoptosis | |||
| 14 | Nanoparticle triggered regulated necrosis | |||
| 15 | Amyotrophic lateral sclerosis (ALS) | |||
| 16 | Adipogenesis | |||
| 17 | Allograft Rejection | |||
| 18 | TNF alpha Signaling Pathway | |||
| 19 | TWEAK Signaling Pathway | |||
| 20 | Extrinsic Pathway for Apoptosis | |||
| 21 | Folate Metabolism | |||
| 22 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 23 | Vitamin B12 Metabolism | |||
| 24 | Selenium Micronutrient Network | |||
| 25 | Regulation of toll-like receptor signaling pathway | |||
| 26 | Matrix Metalloproteinases | |||